



Biotech Daily

Thursday January 30, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: GENETIC SIGNATURES UP 21%
- PHARMAXIS DOWN 8%**
- * **FEDERAL \$5m FOR LUNG CANCER GENOMICS RESEARCH**
- * **BIOTECH DAILY APPENDIX 4C QUARTERLY REPORTS POLICY**
- * **CELLMID H1 RECEIPTS UP 54% TO \$4.8m**
- * **GENETIC SIGNATURES H1 RECEIPTS UP 25% TO \$2.9m**
- * **PHARMAUST H1 RECEIPTS DOWN 5.6% TO \$1.9m**
- * **HERAMED HAS LESS THAN TWO QUARTERS CASH**
- * **US PATENT FOR ADALTA AD-214 FOR FIBROTIC DISEASE**
- * **SIENNA APPOINTS DR RAOUL CONCEPCION ADVISOR**

MARKET REPORT

The Australian stock market fell 0.33 percent on Thursday January 30, with the ASX200 down 23.1 points to 7,008.4 points. Thirteen of the Biotech Daily Top 40 stocks were up, 22 fell, two traded unchanged and three were untraded. All three Big Caps fell.

Genetic Signatures was the best, up 21 cents or 21 percent to \$1.21, with 971,107 shares traded, followed by Immutep up 20.7 percent to 35 cents with 7.1 million shares traded.

Oncosil climbed 14.3 percent; Optiscan was up 9.7 percent; Alterity and Patrys were up five percent or more; Impedimed improved four percent; Imugene was up three percent; Ellex, Next Science and Resonance rose two percent or more; with Polynovo and Telix up by less than one percent.

Pharmaxis led the falls, down one cent or eight percent to 11.5 cents with 771,332 shares traded.

Avita lost 7.25 percent; Medical Developments shed 6.9 percent; Clinuvel, Kazia and Pro Medicus fell more than four percent; Cynata, LBT, Opthea, Osprey and Prescient were down more than three percent; Paradigm, Starpharma and Universal Biosensors shed more than two percent; Antisense, Compumedics, CSL, Mesoblast, Neuren, Orthocell, Proteomics and Volpara were down one percent or more; with Cochlear, Nanosonics and Resmed down by less than one percent.

FEDERAL GOVERNMENT

The Federal Government says it will provide \$5 million for a genomics project to support personalized treatments for patients with lung cancer.

A media-release from Health Minister Greg Hunt said the 'Aspiration' project was jointly funded through the \$20 billion Medical Research Future Fund and by the Basel, Switzerland-based Roche Pharmaceuticals.

The Government said the study was a genomic profiling research project for 1,000 Australians with newly diagnosed metastatic, non-squamous, non-small cell lung cancer, and each patient would have their disease tested "in a process known as comprehensive genomic profiling".

The media release said that the information would be used to improve and optimize treatment decisions.

The Federal Government said that "targeted therapies reduce side effects, avoid unnecessary treatments and offer new hope ... [and the study would] also serve as a blueprint for how precision medicine, enabled by genomics, can become a standard-of-care in treating lung cancer in Australia".

The Government said that the study would begin commence enrollment from July 2020 and be conducted by the Australian Genomic Cancer Medicine Centre, the Australasian Lung Cancer Trials Group and the National Health and Medical Research Council Clinical Trials Centre.

The media release said that more than 12,800 new cases of lung cancer were diagnosed in Australia in 2019, with more than 9,000 deaths.

BIOTECH DAILY APPENDIX 4C REPORTS

Biotech Daily reports all the significant announcements to the ASX.

Biotechnology companies bleeding money is not news, unless the company involved has less than two quarters of cash.

When companies clearly explain that they expect an R&D Tax Incentive, have equity draw-down facilities or loans, or are about to cut costs, have revenue or conduct a capital raising, Biotech Daily will not report their Appendix 4C statement.

Where there is no explanation, or it is not clear, and the company has less than six months of cash reserves, it will be reported, as will maiden revenues or profits.

Biotech Daily has set a bar of \$2 million in receipts from customers in one quarter, half year or full year, as a minimum, apart from companies posting their first \$1 million in receipts or revenue.

Companies reporting after the close of business will be reported in the following edition.

David Langsam
Editor

CELLMID

Cellmid says receipts from customers for the six months to December 31, 2019 were up 54.4 percent to \$4,770,000.

Cellmid said consumer health product sales, primarily its hair growth products, were up 19 percent to \$2.45 million for the three months to December 31, 2019, compared to the previous corresponding period.

The company said it had \$3,885,000 in cash and cash equivalents at December 31, 2019 and expected to spend \$2,650,000 for the three months to March 31, 2020.

Cellmid fell one cent or 4.55 percent to 21 cents.

GENETIC SIGNATURES

Genetic Signatures says receipts from customers for the six months to December 31, 2019 were up 24.7 percent to \$2,871,000.

Genetic Signatures said it had cash and cash equivalents of \$40,441,000 at December 31, 2019 and expected a cash burn of \$3,419,000 for the three months to March 31, 2020. Genetic Signatures was up 21 cents or 21 percent to \$1.21 with 971,107 shares traded.

PHARMAUST

Pharmaust says receipts from customers for the six months to December 31, 2019 fell 5.6 percent to \$1,804,000, compared to the previous corresponding period.

Pharmaust said that receipts, primarily from its Epichem medicinal chemistry division, for the three months to December 31 decreased 11.4 percent to \$710,000.

The company said it had \$2,922,000 in cash and cash equivalents at December 31 with an expected expenditure for the three months to March 31, 2019 of \$1,500,000.

Pharmaust fell one cent or eight percent to 11.5 cents.

HERAMED

Heramed says it had \$US2,045,000 (\$A3,034,003) in cash at December 31, 2019 and expects to spend \$US1,276,000 (\$A1,893,099) in the three months to March 31, 2020.

Heramed said receipts from customers for its foetal heart monitors was \$US206,000 for the six months, and \$US56,000 for the three months, respectively, to December 31, 2019. In December, the company said it raised \$1,423,531 in a placement at 15.5 cents a share (BD: Dec 10, 2019).

Biotech Daily contacted Heramed regarding the apparent deficit of less than two quarters of cash, but at the time of publication, had not received a response.

Heramed was unchanged at 16 cents.

ADALTA

Adalta says the US Patent and Trademark Office has granted a patent relating to its lead program, AD-214, for fibrotic illnesses.

Adalta said the patent, titled 'CXCR4 binding molecules and methods of use thereof', would protect its intellectual property until January 8, 2036.

Adalta was up one cent or 10 percent to 11 cents.

SIENNA CANCER DIAGNOSTICS

Sienna says it has appointed the Nashville, Tennessee-based urologist Dr Raoul Concepcion as the first member of its clinical advisory board.

Sienna said Dr Concepcion was currently an assistant clinical professor at Nashville's Vanderbilt University Medical Centre and was previously president of the Large Urology Group Practice Association.

Sienna was up 0.1 cents or 2.6 percent to four cents.